| Literature DB >> 28836986 |
Ke Chen1, Yu Pan1, Bin Zhang1, Hendi Maher2, Xian-Fa Wang1, Xiu-Jun Cai3.
Abstract
BACKGROUND: Advanced minimally invasive techniques including robotic surgery are being employed with increasing frequency around the world, primarily in order to improve the surgical outcomes of laparoscopic gastrectomy (LG). We conducted a systematic review and meta-analysis to evaluate the feasibility, safety and efficacy of robotic gastrectomy (RG).Entities:
Keywords: Gastrectomy; Laparoscopy; Meta-analysis; Morbidity; Robot; Stomach neoplasms
Mesh:
Year: 2017 PMID: 28836986 PMCID: PMC5571509 DOI: 10.1186/s12893-017-0290-2
Source DB: PubMed Journal: BMC Surg ISSN: 1471-2482 Impact factor: 2.102
Fig. 1Flow chart of literature search strategies
Summary of studies included in the meta-analysis
| Author | Region | Study design | Year | Study | Sample size | Level of lymphadenectomy | Surgical extension | Reconstruction | Conversion (%) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| LG | RG | LG | RG | ||||||||
| Pugliese | Italy | OCS (R) | 2010 | 2000–2009 | 48 | 16 | D2 | D | R-Y | 3(6) | 2(12) |
| Kim MC | Korea | OCS (P) | 2010 | 2007–2008 | 11 | 16 | D1 + β, D2 | D | B-I, B-II | 0 | 0 |
| Kim KM | Korea | OCS (P) | 2012 | 2005–2010 | 861 | 436 | D1 + α/β, D2 | D, T | B-I, B-II, R-Y | NR | NR |
| Son SY | Korea | OCS (R) | 2012 | 2007–2011 | 42 | 21 | D1 + β, D2 | D, P, T | B-I, B-II, R-Y | NR | NR |
| Kang | Korea | OCS (P) | 2012 | 2008–2011 | 282 | 100 | D1 + α/β, D2 | D, T | B-I, B-II, R-Y | E | 0 |
| Zhang | China | OCS (R) | 2012 | 2009–2011 | 70 | 97 | D2 | D, P, T | B-I, B-II, R-Y | 0 | 0 |
| Hyun | Korea | OCS (P) | 2013 | 2009–2010 | 83 | 38 | D1 + α/β, D2 | D, T | B-I, B-II, R-Y | 0 | 0 |
| Son T | Korea | OCS (R) | 2014 | 2003–2010 | 58 | 51 | D2 | T | R-Y | 0 | 0 |
| Noshiro | Japan | OCS (P) | 2014 | 2010–2012 | 160 | 21 | D1 + α/β, D2 | D | B-I, B-II, R-Y | 0 | 0 |
| Huang | Taiwan | OCS (P) | 2014 | 2008–2014 | 73 | 72 | D1 + α/β, D2 | D, T | B-I, R-Y | NR | NR |
| Zhou | China | OCS (R) | 2014 | 2010–2013 | 394 | 120 | D1 + α/β, D2 | D, P, T | B-I, B-II, R-Y | E | E |
| Liu | China | OCS (R) | 2014 | 2012–2013 | 100 | 100 | D2 | D, P, T | B-I, B-II, R-Y | 1(1) | 0 |
| Lee | Korea | OCS (P) | 2015 | 2003–2010 | 267 | 133 | D2 | D | B-I, B-II, R-Y | NR | NR |
| Han | Korea | OCS (R) | 2015 | 2008–2013 | 68 | 68 | D1 + β | PPG | GG | 0 | 0 |
| Park | Korea | OCS (P) | 2015 | 2009–2011 | 612 | 145 | D1 + α/β | D, T | B-I, B-II, R-Y | 10(1.6) | 3(2.0) |
| Suda | Japan | OCS (R) | 2015 | 2009–2012 | 438 | 88 | D1 + α/β, D2 | D, T | B-I, B-II, R-Y | 0 | 0 |
| Kim HI | Korea | OCS (P) | 2016 | 2011–2012 | 185 | 185 | D1 + α/β, D2 | D, T | B-I, B-II, R-Y | 2(1.1) | 1(0.5) |
| Shen | China | OCS (R) | 2016 | 2011–2014 | 330 | 93 | D1 + α/β, D2 | D, T | B-I, B-II, R-Y | 0 | 0 |
| Cianchi | Italy | OCS (R) | 2016 | 2008–2015 | 41 | 30 | D1 + α/β, D2 | D | B-II, R-Y | 0 | 0 |
OCS observational clinical study, P prospectively collected data, R retrospectively collected data, D distal gastrectomy, P proximal gastrectomy, T total gastrectomy, PPG pylorus-preserving gastrectomy, B-I Billroth-I, B-II Billroth-II, R-Y Roux-en-Y, GG gastro-gastro anastomosis, E exclude, NR not reported
Quality assessment based on the NOS for observational studies
| Author | Selection (Out of 4) | Comparability (Out of 2) | Outcomes (Out of 3) | Total (Out of 9) | |||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| |||
| Pugliese | * | * | * | * | ** | * | * | * | 9 |
| Kim MC | * | * | * | * | * | * | 6 | ||
| Kim KM | * | * | * | * | * | * | 6 | ||
| Son SY | * | * | * | * | ** | * | 7 | ||
| Kang | * | * | * | * | * | * | 6 | ||
| Zhang | * | * | * | * | ** | * | 7 | ||
| Hyun | * | * | * | * | * | * | 6 | ||
| Son T | * | * | * | * | ** | * | * | * | 9 |
| Noshiro | * | * | * | * | ** | * | 7 | ||
| Huang | * | * | * | * | ** | * | 7 | ||
| Zhou | * | * | * | * | ** | * | * | * | 9 |
| Liu | * | * | * | * | ** | * | 7 | ||
| Lee | * | * | * | * | * | * | * | * | 8 |
| Han | * | * | * | * | ** | * | * | * | 9 |
| Park | * | * | * | * | * | * | 6 | ||
| Suda | * | * | * | * | * | * | * | 7 | |
| Kim HI | * | * | * | * | * | * | 6 | ||
| Shen | * | * | * | * | ** | * | 7 | ||
| Cianchi | * | * | * | * | * | * | 6 | ||
①representativeness of exposed cohort
②selection of nonexposed cohort
③ascertainment of exposure
④outcome not present at the start of the study
⑤assessment of outcomes
⑥length of follow-up
⑦adequacy of follow-up
Fig. 2Forest plot of the meta-analysis for intraoperative effects and postoperative recovery. a Operation time. b Estimated blood loss. c Time to first flatus. d Time to restart oral intake. e Length of postoperative hospital stay
Results of the meta-analysis
| Outcomes | No. of studies | Sample size | Heterogeneity ( | Overall effect size | 95% CI of overall effect |
| |
|---|---|---|---|---|---|---|---|
| LG | RG | ||||||
| Conversion | 4 | 16 | 6 | 0.68, 0% | RR =0.88 | 0.36 ~ 2.17 | 0.78 |
| Operation time (min) | 19 | 4123 | 1830 | <0.001, 88% | WMD = −49.05 | -58.18 ~ −39.91 | <0.01 |
| Blood loss (mL) | 18 | 4055 | 1762 | <0.001, 93% | WMD =24.38 | 12.32 ~ 36.43 | <0.01 |
| Time to first flatus (days) | 9 | 1231 | 713 | <0.001, 74% | WMD =0.09 | -0.10 ~ 0.27 | 0.36 |
| Time to oral intake (days) | 9 | 2055 | 1096 | 0.67, 0% | WMD =0.23 | 0.13 ~ 0.34 | <0.01 |
| Hospital stay (days) | 19 | 4123 | 1830 | <0.001, 82% | WMD =0.35 | -0.25 ~ 0.95 | 0.25 |
| Overall complications | 19 | 4123 | 1830 | 0.82, 0% | RR =0.96 | 0.82 ~ 1.13 | 0.65 |
| Surgical complications | 17 | 3234 | 1552 | 0.52, 0% | RR =0.87 | 0.72 ~ 1.05 | 0.15 |
| Medical complications | 12 | 2137 | 907 | 0.82, 0% | RR =1.34 | 0.75 ~ 2.40 | 0.32 |
| Reoperation | 7 | 1796 | 789 | 0.35, 11% | RR =0.69 | 0.29 ~ 1.62 | 0.39 |
| Mortality | 7 | 2131 | 838 | 0.91, 0% | RR =0.67 | 0.26 ~ 1.74 | 0.41 |
| Retrieved lymph nodes | 17 | 3229 | 1585 | <0.001, 86% | WMD = −1.44 | -3.26 ~ 0.37 | 0.12 |
| Proximal margin (cm) | 9 | 2006 | 1024 | 0.21, 26% | WMD = −0.14 | -0.36 ~ 0.07 | 0.18 |
| Distal margin (cm) | 8 | 1948 | 973 | <0.001, 81% | WMD =0.09 | -0.46 ~ 0.65 | 0.74 |
| Recurrence | 3 | 500 | 187 | 0.39, 0% | RR =1.09 | 0.57 ~ 2.05 | 0.80 |
| Cost (USD) | 4 | 390 | 384 | <0.001, 93% | WMD = −3944.8 | -4943.5 ~ −2946.2 | <0.01 |
Fig. 3Forest plot of the meta-analysis for morbidity and mortality. a Overall postoperative complications. b Surgical complications. c Medical complications. d Reoperation. e Mortality
Fig. 4Funnel plot of the overall postoperative complications
Systematic review of the specific reoperation and death reasons
| Author | Group | Reoperation | Death |
|---|---|---|---|
| Pugliese | LG | Enterocutaneous leak ( | Severe bleeding due to hepatic failure ( |
| RG | NC | Hemorrhagic stroke ( | |
| Kim KM | LG | Leak-related ( | Leak-related ( |
| RG | Leak-related ( | NC | |
| RG | Leakage and obstruction ( | NC | |
| Lee | LG | Anastomotic leakage ( | NC |
| RG | Anastomotic leakage ( | Anastomotic bleeding ( | |
| Huang | LG | NC | Duodenal stump leakage ( |
| RG | NC | Gastrojejunostomy leakage ( | |
| Han | LG | Intra-abdominal bleeding due to liver capsular injury ( | NC |
| Park | LG | NC | Immediate postoperative bleeding ( |
| Cianchi | LG | NC | Duodenal stump leakage with peritonitis and sepsis ( |
| RG | Intestinal occlusion ( | Cerebral vascular accident ( |
NC no case
a: included anastomotic leakage and duodenal stump leakage
Fig. 5Forest plot of the meta-analysis for oncologic outcomes. a Number of retrieved lymph nodes. b Proximal margin distances. c Distal margin distance. d Cancer recurrence
Systematic Review of Recurrence and Long-term Survivals
| Author | Group | Stage | Chemotherapy | Follow-up (mo) | Recurrence | Survival (%) |
|---|---|---|---|---|---|---|
| Pugliese | LG | Any TNM0 | T3 or any TN+ | 53 (3–112) | 8a | 3y–OS: 85; 5y–OS: 83& |
| RG | 28 (2–44) | 4a | 3y–OS: 78& | |||
| Son T | LG | Any TNM0 | NR | 70 | 3b | 5y–DFS: 91.2; 5y–OS: 91.1 |
| RG | 3b | 5y–DFS: 90.2; 5y–OS: 89.5 | ||||
| Zhou | LG | Any TNM0 | Routinely# | 17(3–41) | 28 | 1, 2, 3-OS: 87.3, 77.1, 69.9 |
| RG | 5 | 1, 2, 3-OS: 90.2, 78.1, 67.8 | ||||
| Lee | LG | Any TNM0 | NR | 75 | NR | NSD |
| RG | ||||||
| Han | LG | cT1-2N0M0 | 3 cases (4.4%)$ | 19.3 | 0 | NSD |
| RG | 3 cases (4.4%)$ | 22.7 | 0 |
Follow-up time were shown as median (range) or median only
DFS disease-free survival, OS overall survival, y year, N − negative nodal metastasis, N positive nodal metastasis, NR not report, NSD only reported no significant difference between two groups without specific survival rate
asome patients had mixed tumor recurrence, identified recurrence in LG: local (n = 2), peritoneum (n = 2), liver (n = 1), lung (n = 2), bone (n = 1); identified recurrence in RG: peritoneum (n = 1), liver (n = 1), bone (n = 1). &: for overall patients, 5y–OS N−: 97%, 5y–OS N+: 52%
bLG, peritoneum (n = 2), lung (n = 1); RG, breast (n = 1), splenic hilum (n = 1), ovary (n = 1). #: 5-fluorouracil + oxaliplatin intravenous chemotherapy. $: because of advanced disease status after surgery
Fig. 6Forest plot of the meta-analysis for total cost
Results of the subgroup analysis of distal or total gastrectomy
| Outcomes | No. of studies | Sample size | Heterogeneity ( | Overall effect size | 95% CI of overall effect |
| |
|---|---|---|---|---|---|---|---|
| LG | RG | ||||||
| Operation time (min) | |||||||
| DG | 8 | 1635 | 453 | <0.001, 78% | WMD = −57.08 | −68.62 ~ −45.54 | <0.01 |
| TG | 5 | 448 | 166 | 0.004, 74% | WMD = −42.62 | −66.72 ~ −18.52 | <0.01 |
| Blood loss (mL) | |||||||
| DG | 8 | 1635 | 453 | <0.001, 77% | WMD =19.27 | 3.86 ~ 34.68 | 0.01 |
| TG | 5 | 448 | 166 | 0.54, 0% | WMD =23.77 | 1.97 ~ 45.56 | 0.03 |
| Time to oral intake (days) | |||||||
| DG | 3 | 344 | 116 | 0.49, 0% | WMD =0.18 | 0.00 ~ 0.36 | 0.05 |
| TG | 3 | 251 | 100 | 0.71, 0% | WMD = −0.18 | −0.55 ~ 0.20 | 0.36 |
| Hospital stay (days) | |||||||
| DG | 8 | 1635 | 453 | <0.001, 92% | WMD =0.52 | −0.69 ~ 1.74 | 0.40 |
| TG | 5 | 448 | 166 | 0.75, 0% | WMD =0.28 | −0.80 ~ 1.36 | 0.61 |
| Overall complications | |||||||
| DG | 8 | 1635 | 453 | 0.86, 0% | RR =1.19 | 0.83 ~ 1.71 | 0.34 |
| TG | 4 | 330 | 140 | 0.49, 0% | RR =1.32 | 0.80 ~ 2.18 | 0.27 |
| Mortality | |||||||
| DG | 4 | 942 | 213 | 0.84, 0% | RR =0.84 | 0.21 ~ 3.30 | 0.80 |
| TG | 2 | 194 | 81 | 0.55, 0% | RR =0.15 | 0.02 ~ 1.41 | 0.10 |
| Retrieved lymph nodes | |||||||
| DG | 8 | 1635 | 453 | <0.001, 92% | WMD = −2.10 | −5.90 ~ 1.70 | 0.28 |
| TG | 5 | 448 | 166 | 0.63, 0% | WMD = −2.51 | −4.83 ~ −0.19 | 0.03 |
DG distal gastrectomy, TG total gastrectomy
Results of the subgroup analysis of weight
| Outcomes | No. of studies | Sample size | Heterogeneity ( | Overall effect size | 95% CI of overall effect |
| |
|---|---|---|---|---|---|---|---|
| LG | RG | ||||||
| Operation time (min) | |||||||
| non-overweight | 2 | 232 | 127 | 0.06, 72% | WMD = −37.63 | −62.82 ~ −12.43 | <0.01 |
| overweight | 2 | 118 | 44 | 0.008, 86% | WMD = −28.58 | −79.11 ~ 21.94 | 0.27 |
| Blood loss (mL) | |||||||
| non-overweight | 2 | 232 | 127 | 0.11, 60% | WMD =0.90 | −13.44 ~ 15.25 | 0.90 |
| overweight | 2 | 118 | 44 | 0.03, 80% | WMD =39.84 | −41.71 ~ 121.39 | 0.34 |
| Retrieved lymph nodes | |||||||
| non-overweight | 2 | 232 | 127 | 0.34, 0% | WMD = −1.88 | −4.78 ~ 1.01 | 0.20 |
| overweight | 2 | 118 | 44 | 0.03, 79% | WMD =4.32 | −4.10 ~ 12.74 | 0.31 |